|
Market Report
|
ADHD - Immature adult market continues to offer greatest commercial
The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the 2006 launch of Daytrana have served to open up the market, giving patients and physicians a greater choice of treatment options.
|
|
Read more...
|
|
|
Market Report
|
Breast Cancer - Recent approvals increase pressure on pipeline candidates
Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large patient potential make breast cancer a relatively attractive indication for drug developers.
|
|
Read more...
|
|
|
Market Report
|
Heart Failure - When drugs do not work
Advanced heart failure is a growing issue. Existing pharmacological strategies increase the survival rates of acute heart failure patients, providing a growing source of patients with advanced disease. In view of long waiting lists for heart transplantation and the growing lack of donors, cardiac resynchronization and mechanical circulatory support devices have demonstrated promising results.
|
|
Read more...
|
|
|
Market Report
|
Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements
Non-small cell lung cancer accounts for about 80% of all lung cancers. In 2008, the incidence of NSCLC is forecast to exceed 367,000 new cases in the seven major pharmaceutical markets. The high incidence of the disease and the large unmet need make NSCLC an attractive market for new drug development.
|
|
Read more...
|
|
|
Market Report
|
HRT for Menopausal Symptoms – A new class restores an old market
In 2007, the market value of HRT for menopausal symptoms saw its first upturn since the Women’s Health initiative (WHI) study results in 2002; highly publicized findings which linked HRT to cancer and cardiovascular safety risks. The recent growth of the market is due in part to the increasing price of HRT products but can only be sustained by a similar increase in volume sales.
|
|
Read more...
|
|
|
Market Report
|
CNS Market Overview
The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.
|
|
Read more...
|
|
|
Market Report
|
MARKET RESEARCH OF DRUGS USED IN
ATOPIC RHINITIS IN INDIA
The present paper enumerates the pathophysiological conditions of
atopic rhinitis and emphasis was made to gather the information about the drugs
and to reveal the present status in the market. During the course of present
survey of the drugs used in atopic rhinitis, it was found that cetrizine and
levocetrizine (antihistamines-II generation), are widely used in Indore
locality.
|
|
Read more...
|
|
|
Market Report
|
Pharmaceutical Market Trends in 2007
“In 2007, the market will still be absorbing changes that have defined a new economic reality, one in which growth is shifting from mature markets to emerging ones; new product adoption is not keeping pace with the loss of patent protection by established products; specialty and niche products are playing a larger role; and regulators, payers and consumers are more carefully weighing the risk/benefit factors of pharmaceuticals.”, says Murray Aitken, Senior VP, Corporate Strategy at IMS.
|
|
Read more...
|
|
|
Market Report
|
Albania - Pharmaceuticals and Health Care Technology Assessment
Albania has embarked upon major health sector reforms, but it is greatly hampered by political instability and a struggling economy. Nevertheless, the population enjoys reasonable health according to key indicators such as life expectancy, a situation that is particularly impressive in a context of widespread poverty and very low spending on health care.
|
|
Read more...
|
|
|
<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>
|
| Results 271 - 279 of 359 |
Farmavita.Net Journal 
